实用医学杂志 ›› 2021, Vol. 37 ›› Issue (8): 1060-1067.doi: 10.3969/j.issn.1006⁃5725.2021.08.019

• 药物与临床 • 上一篇    下一篇

孟鲁司特治疗血清白三烯增高、呼出气一氧化氮阳性咳嗽变异性哮喘患者的效果

邸金娜,隋丽云, 张莉, 刘敬禹   

  1. 1 锦州医科大学附属第三医院呼吸科(辽宁锦州 121001);2 朝阳市中心医院超声科(辽宁朝阳 122000)

  • 出版日期:2021-04-25 发布日期:2021-04-25
  • 通讯作者: 张莉 E⁃mail:zhangli80809@126.com
  • 基金资助:
    辽宁省重点研发计划项目(编号:2019JH2/10300046)

Clinical efficacy of montelukast in patients with elevated serum LTC4 and FeNO ⁃ positive cough variant asthma

DI Jinna,SUI Liyun,ZHANG Li,LIU Jingyu.
  

  1. Department of Respiratory,Jinzhou Medical University Third Hospital,Jinzhou 121001,China

  • Online:2021-04-25 Published:2021-04-25
  • Contact: ZHANG Li E⁃mail:zhangli80809@126.com

摘要:

目的 探讨孟鲁司特对不同血清白三烯 LTC4 及呼出气一氧化氮(FeNO)水平成人咳嗽变异性哮喘患者的临床疗效及预后研究。方法 选取本院呼吸科门诊初诊为咳嗽变异性哮喘(cough variant asthma,CVA)的患者 120 例为研究组,分为 A 组(血清 LTC4 增高、FeNO 阴性组)、B 组(血清 LTC4 增高、 FeNO 阳性组)、C 组(血清 LTC4 不高、FeNO 阳性组)、D 组(血清 LTC4 不高、FeNO 阴性组),每组各 30 例。 另选择 30 例健康人作为对照组。A、B、C、D 四组均应用孟鲁司特 10 mg 每晚 1 次口服治疗,治疗 1、3 个月 后分别进行咳嗽严重症状评分、LTC4、PEF、FeNO 水平疗效评价,治疗结束后随访 3 个月。结果 A 组受 试者治疗 1、3 个月后咳嗽症状缓解,血清 LTC4 水平、PEF 变异率均减低,差异有统计学意义(P < 0.05);B 组受试者治疗 1、3 个月后咳嗽症状缓解,血清 LTC4 水平、FeNO 水平、PEF 变异率均减低,差异有统计学意义(P < 0.05);两组疗效差异无统计学意义(P > 0.05)。C 组受试者治疗1个月后咳嗽症状略缓解,FeNO 水平、PEF 变异率略减低,差异无统计学意义(P > 0.05);D 组受试者治疗 1 个月后咳嗽症状略缓解,PEF 变异 率略减低,差异无统计学意义(P > 0.05)。结论 孟鲁司特对血清 LTC4 增高的成人 CVA 患者临床疗效好,对血清LTC4不高的成人CVA 患者临床疗效差。在3个月有效治疗期间,治疗时间越长,疗效越好。

关键词:

Abstract:

Objective To explore the clinical efficacy of montelukast in the treatment of patients with elevated serum LTC4 and FeNO⁃positive cough variant asthma as well as its prognosis. Methods A total of 120 patients with cough variant asthma(CVA)were selected from the outpatient department of the respiratory department of our hospital and divided into groups A(increased serum LTC4,FeNO negative group),B(increased serum LTC4 FeNO positive group),C(low serum LTC4,FeNO positive group),and D(low serum LTC4,FeNO negative group),30 cases in each group. Another 30 healthy people were selected as the control group. All groups A,B,C and D received oral treatment of 10 mg montelukast once a night. After 1 month and 3 months of treatment,the efficacy of severe cough symptom score,LTC4,PEF and FeNO levels were evaluated respectively,and the patients were followed up for 3 months after the treatment. Follow ⁃ up visits were conducted for 3 months after the end of treatment. Results In group A,the cough symptoms were relieved after 1 month and 3 months of treatment,and the serum LTC4 level and PEF mutation rate were significantly reduced(P < 0.05). The cough symptoms in group B were relieved after 1 month and 3 months of treatment,and the serum LTC4 level,FeNO level,and PEF mutation rate were all reduced,the difference was statistically significant(P < 0.05);there was no statistical difference in the efficacy between the two groups(P > 0.05). The cough symptoms of the subjects in group C were slightly relieved after 1 month of treatment,FeNO levels and the PEF variation rate was slightly reduced,without statistically signifi⁃ cant difference(P > 0.05). After 1 month of treatment,the cough symptoms in group D were slightly relieved and the PEF variation insignificantly reduced(P > 0.05). Conclusion Montelukast has a good clinical effect in the treatment of adult CVA patients with elevated serum LTC4,but it is poor clinically for treating adult CVA patients with low serum LTC4. During the effective treatment period of 3 months,the longer the treatment duration is,the better the effect.

Key words: